<DOC>
	<DOCNO>NCT00093951</DOCNO>
	<brief_summary>The purpose trial determine effect new drug , SGS742 , memory cognition patient mild moderate Alzheimer 's disease .</brief_summary>
	<brief_title>SGS742 Patients With Mild Moderate Alzheimer 's Disease ( AD )</brief_title>
	<detailed_description>SGS742 GABA ( B ) receptor antagonist . It orally active drug posse neurochemical psychopharmacologic feature suggest could improve memory cognition human . The primary objective SGS742 clinical trial determine effect SGS742 memory cognition individual diagnose mild moderate Alzheimer 's disease . The duration study 3 month 5 clinic visit .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>( 3-aminopropyl ) ( n-butyl ) phosphinic acid</mesh_term>
	<criteria>55 90 year age Diagnosed mild moderate Alzheimer 's disease Willing caregiver In general good health Call 1877MYMEMORY ask refer study center locate near entry criterion information . Prohibited Meds : Alzheimer 's medication ( Aricept , Exelon , Remydl , Nemenda )</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Alzheimer disease</keyword>
	<keyword>memory</keyword>
	<keyword>cognition</keyword>
	<keyword>GABA ( B ) receptor antagonist</keyword>
</DOC>